Kura forms Caspian and retains 49.2% stake
Kura formed Caspian Therapeutics, contributed next-generation menin inhibitor assets and retained approximately 49.2% after a $50.0 million Series A financing.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.